Spots Global Cancer Trial Database for recurrent hodgkin lymphoma

Every month we try and update this database with for recurrent hodgkin lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	NCT03013933	Recurrent Hodgk... Refractory Hodg...	Brentuximab Ved... Cyclosporine Pharmacokinetic... Verapamil Verapamil Hydro...	15 Years -	City of Hope Medical Center
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation	NCT03602898	Acute Lymphobla... Acute Myeloid L... Chronic Myelomo... Chronic Phase C... Hematopoietic a... Myelodysplastic... Myelofibrosis Myeloproliferat... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Refractory Acut... Therapy-Related...	Anti-Thymocyte ... Busulfan Cyclophosphamid... Cyclosporine Fludarabine Pho... Methotrexate Peripheral Bloo... Quality-of-Life... Questionnaire A... Tacrolimus Total-Body Irra...	- 65 Years	Fred Hutchinson Cancer Center
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant	NCT01822509	Allogeneic Hema... Myeloproliferat... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Chron... Recurrent Hemat... Recurrent Hodgk... Recurrent Myelo... Recurrent Non-H... Recurrent Plasm...	Ipilimumab Laboratory Biom... Nivolumab	18 Years -	National Cancer Institute (NCI)
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis	NCT02593123	Hodgkin's Lymph... Lymphoid Leukem... Lymphoma Leukemia Myeloma Acute Lymphocyt... Non Hodgkin Lym... Chronic Lymphoc... Multiple Myelom... Chronic Myeloge... Myelodysplastic... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Recurrent Plasm... Recurrent Chron... Recurrent Chron... Acute Myelogeno...	mycophenolate m... Sargramostim Filgrastim	18 Years - 74 Years	Virginia Commonwealth University
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	NCT02254239	Recurrent Hodgk... Refractory Hodg...	Brentuximab Ved... Everolimus Laboratory Biom... Pharmacological...	18 Years -	Mayo Clinic
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant	NCT01251575	Adult Acute Lym... Adult Acute Mye... Adult Diffuse L... Adult Myelodysp... Adult Non-Hodgk... Aggressive Non-... Childhood Acute... Childhood Acute... Childhood Diffu... Childhood Myelo... Childhood Non-H... Chronic Lymphoc... Chronic Lymphoc... Chronic Phase C... Hematopoietic a... Mantle Cell Lym... Plasma Cell Mye... Prolymphocytic ... Recurrent Chron... Refractory Chro... T-Cell Prolymph... Waldenstrom Mac... Recurrent Diffu... Recurrent Hodgk...	Allogeneic Hema... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra...	-	Fred Hutchinson Cancer Center
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	NCT02254239	Recurrent Hodgk... Refractory Hodg...	Brentuximab Ved... Everolimus Laboratory Biom... Pharmacological...	18 Years -	Mayo Clinic
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant	NCT02869633	Blastoid Varian... Recurrent Chron... Recurrent Folli... Recurrent Hodgk... Recurrent Mantl... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Mant...	Ibrutinib Laboratory Biom...	18 Years -	Vanderbilt-Ingram Cancer Center
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma	NCT04640779	Recurrent Histi... Recurrent Hodgk... Recurrent Non-H... Recurrent Plasm... Refractory Hist... Refractory Hodg... Refractory Non-... Refractory Plas...	Choline Salicyl... Selinexor	18 Years -	Mayo Clinic
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	NCT02824029	Classical Hodgk... Recurrent Hodgk... Refractory Hodg...	Ibrutinib Laboratory Biom... Pharmacological...	18 Years -	Barbara Ann Karmanos Cancer Institute
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma	NCT05272384	Recurrent B-Cel... Recurrent Diffu... Recurrent Hodgk... Refractory B-Ce... Refractory Diff... Refractory Hodg...	Biospecimen Col... Computed Tomogr... Decitabine and ... Nivolumab Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies	NCT04681105	Recurrent Acute... Recurrent B Acu... Recurrent Blast... Recurrent Chron... Recurrent Hairy... Recurrent Hemat... Recurrent Hodgk... Recurrent T Acu... Refractory Acut... Refractory B Ac... Refractory Blas... Refractory Chro... Refractory Hair... Refractory Hema... Refractory Hodg... Refractory T Ac... Systemic Mastoc...	Acetaminophen Dexamethasone Diphenhydramine Flotetuzumab Ibuprofen Ranitidine	12 Years -	City of Hope Medical Center
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant	NCT01251575	Adult Acute Lym... Adult Acute Mye... Adult Diffuse L... Adult Myelodysp... Adult Non-Hodgk... Aggressive Non-... Childhood Acute... Childhood Acute... Childhood Diffu... Childhood Myelo... Childhood Non-H... Chronic Lymphoc... Chronic Lymphoc... Chronic Phase C... Hematopoietic a... Mantle Cell Lym... Plasma Cell Mye... Prolymphocytic ... Recurrent Chron... Refractory Chro... T-Cell Prolymph... Waldenstrom Mac... Recurrent Diffu... Recurrent Hodgk...	Allogeneic Hema... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra...	-	Fred Hutchinson Cancer Center
NK Cells in Cord Blood Transplantation	NCT01619761	Accelerated Pha... Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... Chronic Phase C... DS Stage II Pla... DS Stage III Pl... High Grade B-Ce... ISS Stage II Pl... ISS Stage III P... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Hodgk... Recurrent Non-H... Recurrent Small... Refractory Acut... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... Secondary Acute... Therapy-Related... Therapy-Related...	Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Lenalidomide Melphalan Mycophenolate M... Natural Killer ... Rituximab Tacrolimus Total-Body Irra... Umbilical Cord ...	- 75 Years	M.D. Anderson Cancer Center
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia	NCT03418038	Clonal Cytopeni... High Grade B-Ce... Recurrent Diffu... Recurrent Hodgk... Recurrent Lymph... Refractory Diff... Refractory Lymp... Chronic Myelomo...	Ascorbic Acid Carboplatin Cisplatin Cytarabine Dexamethasone Etoposide Gemcitabine Hyd... Ifosfamide Laboratory Biom... Oxaliplatin Placebo Adminis... Questionnaire A... Rituximab Decitabine Biospecimen Col... Core Biopsy Bone Marrow Asp... Bone Marrow Bio... Echocardiograph... Positron Emissi... Magnetic Resona... Central Venous ... Portacath Place... Computed Tomogr...	18 Years -	Mayo Clinic
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	NCT02227199	Recurrent Hodgk... Refractory Hodg...	Brentuximab Ved... Carboplatin Etoposide Ifosfamide Laboratory Biom...	18 Years -	University of Washington
Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma	NCT02378922	AIDS-Related Ho... AIDS-Related No... HIV Infection Recurrent Hodgk... Recurrent Non-H...	Gene-Modified H... Laboratory Biom... Transplant Cond...	18 Years - 66 Years	Fred Hutchinson Cancer Center
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma	NCT03096782	Accelerated Pha... Acute Biphenoty... Acute Leukemia Acute Lymphobla... Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chemotherapy-Re... Chronic Lymphoc... Chronic Myeloge... Chronic Myelomo... Hodgkin Lymphom... Langerhans Cell... Minimal Residua... Myelodysplastic... Myelodysplastic... Non-Hodgkin Lym... Recurrent Hodgk... Refractory Acut... Refractory Myel... Small Lymphocyt... Therapy-Related...	Anti-Thymocyte ... Busulfan Clofarabine Cyclophosphamid... Filgrastim-sndz Fludarabine Melphalan Mycophenolate M... Rituximab Tacrolimus Total-Body Irra... Umbilical Cord ...	12 Years - 65 Years	M.D. Anderson Cancer Center
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma	NCT01393717	Recurrent Hodgk... Refractory Hodg...	brentuximab ved...	11 Years -	City of Hope Medical Center
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	NCT02254239	Recurrent Hodgk... Refractory Hodg...	Brentuximab Ved... Everolimus Laboratory Biom... Pharmacological...	18 Years -	Mayo Clinic
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma	NCT01703949	Recurrent Hodgk... Recurrent Non-H... Refractory Hodg... Refractory Non-...	Brentuximab Ved... Laboratory Biom... Nivolumab	18 Years -	University of Washington
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas	NCT01897012	MYC Positive Recurrent B-Cel... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent High ... Recurrent Hodgk... Recurrent Mantl... Recurrent Matur... Refractory B-Ce... Refractory Burk... Refractory Diff... Refractory Foll... Refractory High... Refractory Hodg... Refractory Mant... Refractory Matu...	Alisertib Laboratory Biom... Romidepsin	18 Years -	National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies	NCT01921387	Recurrent B-Cel... Recurrent Hodgk... Recurrent Mantl... Recurrent T-Cel... Refractory B-Ce... Refractory Hodg... Refractory Mant... Refractory T-Ce...	Autologous Hema... Carmustine Cytarabine Etoposide Laboratory Biom... Melphalan Peripheral Bloo... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma	NCT00860171	Recurrent B-Cel... Recurrent Hodgk... Recurrent T-Cel... Refractory B-Ce... Refractory Hodg... Refractory T-Ce...	Autologous Hema... Iodine I 131 Mo... Laboratory Biom...	18 Years -	Fred Hutchinson Cancer Center
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia	NCT03418038	Clonal Cytopeni... High Grade B-Ce... Recurrent Diffu... Recurrent Hodgk... Recurrent Lymph... Refractory Diff... Refractory Lymp... Chronic Myelomo...	Ascorbic Acid Carboplatin Cisplatin Cytarabine Dexamethasone Etoposide Gemcitabine Hyd... Ifosfamide Laboratory Biom... Oxaliplatin Placebo Adminis... Questionnaire A... Rituximab Decitabine Biospecimen Col... Core Biopsy Bone Marrow Asp... Bone Marrow Bio... Echocardiograph... Positron Emissi... Magnetic Resona... Central Venous ... Portacath Place... Computed Tomogr...	18 Years -	Mayo Clinic
Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma	NCT02378922	AIDS-Related Ho... AIDS-Related No... HIV Infection Recurrent Hodgk... Recurrent Non-H...	Gene-Modified H... Laboratory Biom... Transplant Cond...	18 Years - 66 Years	Fred Hutchinson Cancer Center
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	NCT02824029	Classical Hodgk... Recurrent Hodgk... Refractory Hodg...	Ibrutinib Laboratory Biom... Pharmacological...	18 Years -	Barbara Ann Karmanos Cancer Institute
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	NCT02824029	Classical Hodgk... Recurrent Hodgk... Refractory Hodg...	Ibrutinib Laboratory Biom... Pharmacological...	18 Years -	Barbara Ann Karmanos Cancer Institute
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma	NCT01703949	Recurrent Hodgk... Recurrent Non-H... Refractory Hodg... Refractory Non-...	Brentuximab Ved... Laboratory Biom... Nivolumab	18 Years -	University of Washington
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma	NCT04871607	Recurrent Hodgk... Refractory Hodg...	Basiliximab Carmustine Cytarabine Etoposide Genetically Eng... Recombinant Gra... Yttrium Y 90 Ba...	18 Years -	City of Hope Medical Center
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation	NCT03602898	Acute Lymphobla... Acute Myeloid L... Chronic Myelomo... Chronic Phase C... Hematopoietic a... Myelodysplastic... Myelofibrosis Myeloproliferat... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Refractory Acut... Therapy-Related...	Anti-Thymocyte ... Busulfan Cyclophosphamid... Cyclosporine Fludarabine Pho... Methotrexate Peripheral Bloo... Quality-of-Life... Questionnaire A... Tacrolimus Total-Body Irra...	- 65 Years	Fred Hutchinson Cancer Center
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma	NCT04640779	Recurrent Histi... Recurrent Hodgk... Recurrent Non-H... Recurrent Plasm... Refractory Hist... Refractory Hodg... Refractory Non-... Refractory Plas...	Choline Salicyl... Selinexor	18 Years -	Mayo Clinic
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL	NCT03016871	Recurrent Hodgk... Refractory Hodg...	Carboplatin Etoposide Ifosfamide Laboratory Biom... Nivolumab	18 Years -	City of Hope Medical Center
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant	NCT00068718	Blast Phase Chr... Recurrent Adult... Recurrent Adult... Recurrent Hodgk... Recurrent Non-H... Recurrent Plasm...	Therapeutic All...	-	Fred Hutchinson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: